Q1 EPS Estimate for Halozyme Therapeutics Raised by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Zacks Research boosted their Q1 2027 earnings per share estimates for shares of Halozyme Therapeutics in a report released on Monday, February 2nd. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $1.63 per share for the quarter, up from their previous forecast of $1.55. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.27 earnings per share.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Morgan Stanley lowered their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $74.45 on Tuesday. The firm has a 50 day moving average of $68.94 and a 200-day moving average of $68.64. The company has a market cap of $8.76 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.31 and a beta of 0.97. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics has a 52 week low of $47.50 and a 52 week high of $79.50.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. lifted its position in shares of Halozyme Therapeutics by 353.6% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,447 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 1,128 shares during the last quarter. Hussman Strategic Advisors Inc. increased its stake in shares of Halozyme Therapeutics by 66.7% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock worth $3,533,000 after purchasing an additional 21,000 shares in the last quarter. Artemis Investment Management LLP lifted its stake in shares of Halozyme Therapeutics by 14.6% during the 4th quarter. Artemis Investment Management LLP now owns 114,596 shares of the biopharmaceutical company’s stock valued at $7,712,000 after buying an additional 14,638 shares in the last quarter. Sigma Planning Corp boosted its holdings in Halozyme Therapeutics by 22.2% in the 4th quarter. Sigma Planning Corp now owns 9,592 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 1,741 shares during the period. Finally, New York State Teachers Retirement System raised its holdings in Halozyme Therapeutics by 0.7% during the 4th quarter. New York State Teachers Retirement System now owns 125,968 shares of the biopharmaceutical company’s stock valued at $8,478,000 after acquiring an additional 853 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the transaction, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at $48,844,913.48. This trade represents a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 41,398 shares of company stock worth $2,861,352 over the last quarter. Company insiders own 2.90% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.